Common GLP-1 mistakes: what TikTok gets right and wrong

What's this video probably claiming?

Based on the caption and hashtag framing, @bossfidence is likely running through a shortlist of behavioral or dosing-adjacent mistakes that GLP-1 users make, probably including things like not eating enough protein, stopping the medication too early, or ignoring side effects instead of managing them. These are genuinely common talking points in the GLP-1 community, and some of them have real clinical backing. The concern with this format, though, is that a 60-second mistake-list video collapses a lot of nuance. What counts as a "mistake" depends heavily on whether someone is on semaglutide for obesity versus type 2 diabetes, what dose they're on, and what their prescribing clinician has told them. Without that context, generic advice can land wrong for a meaningful percentage of viewers.

Expect the video to lean on personal observation rather than cited evidence, which is the norm for this content category. The framing of "mistakes I see" positions the creator as an experienced insider, which may or may not be grounded in any clinical training.

What does the science actually show?

The actual evidence on GLP-1 user behavior and outcomes is more specific than most TikTok videos acknowledge. On protein intake, there is real concern: Wilding et al. (2021, NEJM) found that participants on semaglutide 2.4 mg lost an average of 14.9% of body weight over 68 weeks, but body composition data shows a meaningful proportion of that loss comes from lean mass. A 2023 analysis in Obesity by Bikou et al. confirmed that inadequate protein intake during GLP-1 therapy accelerates muscle loss. The clinical recommendation, at least from dietitians working in obesity medicine, is 1.2 to 1.6 grams of protein per kilogram of body weight daily, though that figure should come from a clinician, not a TikTok video.

On discontinuation, Wharton et al. (2023, Diabetes, Obesity and Metabolism) showed that stopping semaglutide leads to regain of roughly two-thirds of lost weight within one year. That is a real finding, and it matters. But framing continuation as simply a "mistake" to avoid oversimplifies what is actually a shared clinical decision involving insurance, cost, tolerability, and long-term health goals.

Where does the social media noise diverge from clinical reality?

The biggest divergence is around side effect management. TikTok's GLP-1 ecosystem is full of creator-invented workarounds: splitting injections, changing injection timing without clinical guidance, or pairing GLP-1 medications with unregulated supplements to reduce nausea. None of those practices have strong clinical trial support, and some carry real risk. The FDA-approved titration schedules for semaglutide and tirzepatide exist because the dose-escalation data actually matters for tolerability and safety.

There is also a persistent myth that all GLP-1 medications work the same way. Liraglutide (Victoza, Saxenda) has a different half-life than semaglutide, and tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 agonist with a distinct mechanism. Jastreboff et al. (2022, NEJM) showed tirzepatide at 15 mg produced up to 20.9% body weight reduction, meaningfully different from semaglutide's trial outcomes. Treating them interchangeably in "mistake" advice videos flattens clinically relevant distinctions.

What should you actually know?

If you are on a GLP-1 medication, the most evidence-backed behaviors involve three areas: diet composition, consistency, and communication with your prescriber. Protein and resistance training data is real. A 2022 study in the International Journal of Obesity by Cava et al. confirmed that higher protein intake during energy restriction preserves lean mass, and that finding extends logically to GLP-1-assisted weight loss.

Consistency matters too, and not just for weight outcomes. Missing doses or self-adjusting the schedule based on social media advice can affect glycemic control in patients using these drugs for type 2 diabetes, not just weight loss. The stakes are higher than the "tips and tricks" framing suggests.

• Work with a registered dietitian if you can access one, especially in the first 12 weeks when intake drops sharply.
• Do not change your injection site, timing, or dose based on creator recommendations without speaking to your prescribing clinician first.
• Nausea is common and manageable through legitimate titration, not supplement stacking.

The bottom line is that some of what this video likely covers is directionally correct. But a regulated telehealth patient deserves more than directionally correct.